Management of diabetes during Ramadan: an update for Russian-speaking doctors

Fasting during the Islamic Ramadan month is one of the five obligatory pillars for each adult, healthy, and sane Muslim. People with severe illnesses, including type 1 and type 2 diabetes mellitus are exempt from fasting. However, many Muslims often insist on Ramadan participating despite any medical advises. It’s known that Muslims are the second largest religious group in Russia; thus, its crucial to have as much modern recommendation for management patients with type 1 and type 2 diabetes mellitus as possible. The aim of this narrative review is to evaluate physiological and pathophysiological metabolism changing during holy Ramadan month, to clarify the management of patients with type 1 and type 2 diabetes mellitus during Ramadan, to determine the frequency of glucose measuring during the day, and to understand when its time to interrupt the fasting. Moreover, we discuss specific recommendations in glucose-lowering therapy changing, nutrition, physical activities and education.

1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-281. doi: https://doi.org/10.1016/j.diabres.2018.02.023

2. Wikipedia [Internet]. Muslim population growth. 2022. [cited 06.05.2022]. Available from: https://en.wikipedia.org/w/index.php?title=Muslim_population_growth&oldid=1085822338

3. Skol’ko musul’man v Rossii. Kolichestvo priverzhentsev Islama. (In Russ.). Доступно по: https://medinaschool.org/library/obshestvo/istoriya-islama/skolko-musulman-v-rossii. Ссылка активна на 06.05.22.

4. Wikipedia [Internet]. Islam v Rossii. 2022. (In Russ.). Доступно по: https://ru.wikipedia.org/w/index.php?title=%D0%98%D1%81%D0%BB%D0%B0%D0%BC_%D0%B2_%D0%A0%D0%BE%D1%81%D1%81%D0%B8%D0%B8&oldid=121556685. Ссылка активна на 06.05.22.

5. Bouchareb S, Chrifou R, Bourik Z, et al. “I am my own doctor”: A qualitative study of the perspectives and decision-making process of Muslims with diabetes on Ramadan fasting. Schouten B, ed. PLoS One. 2022;17(3):e0263088. doi: https://doi.org/10.1371/journal.pone.0263088

6. IDF Diabetes Atlas. [Интернет].Tenth Edition. [cited 04.05.2022]. Available from: https://diabetesatlas.org/

7. Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27(10):2306-2311. doi: https://doi.org/10.2337/diacare.27.10.2306

8. Babineaux SM, Toaima D, Boye KS, et al. Multi-country retrospective observational study of the management and outcomes of patients with Type 2 diabetes during Ramadan in 2010 (CREED). Diabet Med J Br Diabet Assoc. 2015;32(6):819-828. doi: https://doi.org/10.1111/dme.12685

9. Al Awadi FF, Echtay A, Al Arouj M, et al. Patterns of Diabetes Care Among People with Type 1 Diabetes During Ramadan: An International Prospective Study (DAR-MENA T1DM). Adv Ther. 2020;37(4):1550-1563. doi: https://doi.org/10.1007/s12325-020-01267-4

10. BaHammam A, Alrajeh M, Albabtain M, et al. Circadian pattern of sleep, energy expenditure, and body temperature of young healthy men during the intermittent fasting of Ramadan. Appetite. 2010;54(2):426-429. doi: https://doi.org/10.1016/j.appet.2010.01.011

11. Roky R, Chapotot F, Hakkou F, et al. Sleep during Ramadan intermittent fasting. J Sleep Res. 2001;10(4):319-327. doi: https://doi.org/10.1046/j.1365-2869.2001.00269.x

12. Haouari M, Haouari-Oukerro F, Sfaxi A, et al. How Ramadan fasting affects caloric consumption, body weight, and circadian evolution of cortisol serum levels in young, healthy male volunteers. Horm Metab Res. 2008;40(8):575-577. doi: https://doi.org/10.1055/s-2008-1065321

13. BaHammam AS, Almeneessier AS. Recent Evidence on the impact of Ramadan diurnal intermittent fasting, mealtime, and circadian rhythm on cardiometabolic risk: A review. Front Nutr. 2020;7(08):575-577. doi: https://doi.org/10.3389/fnut.2020.00028

14. Al-Rawi N, Madkour M, Jahrami H, et al. Effect of diurnal intermittent fasting during Ramadan on ghrelin, leptin, melatonin, and cortisol levels among overweight and obese subjects: A prospective observational study. PloS One. 2020;15(8):e0237922. doi: https://doi.org/10.1371/journal.pone.0237922

15. Bahijri S, Borai A, Ajabnoor G, et al. Relative metabolic stability, but disrupted circadian cortisol secretion during the fasting month of Ramadan. PloS One. 2013;8(4):e60917. doi: https://doi.org/10.1371/journal.pone.0060917

16. Shirreffs SM, Maughan RJ. Water and salt balance in young male football players in training during the holy month of Ramadan. J Sports Sci. 2008;26(S3):S47-54. doi: https://doi.org/10.1080/02640410802428097

17. Leiper JB, Molla AM, Molla AM. Effects on health of fluid restriction during fasting in Ramadan. Eur J Clin Nutr. 2003;57(S2):S30-38. doi: https://doi.org/10.1038/sj.ejcn.1601899

18. Ibrahim M, Abu Al Magd M, Annabi FA, et al. Recommendations for management of diabetes during Ramadan: update 2015. BMJ Open Diabetes Res Care. 2015;3(1):e000108. doi: https://doi.org/10.1136/bmjdrc-2015-000108

19. Finch GM, Day JE, Razak, et al. Appetite changes under free-living conditions during Ramadan fasting. Appetite. 1998;31(2):159-170. doi: https://doi.org/10.1006/appe.1998.0164

20. el Ati J, Beji C, Danguir J. Increased fat oxidation during Ramadan fasting in healthy women: an adaptative mechanism for body-weight maintenance. Am J Clin Nutr. 1995;62(2):302-307. doi: https://doi.org/10.1093/ajcn/62.2.302

21. Lessan N, Hannoun Z, Hasan H, et al. Glucose excursions and glycaemic control during Ramadan fasting in diabetic patients: insights from continuous glucose monitoring (CGM). Diabetes Metab. 2015;41(1):28-36. doi: https://doi.org/10.1016/j.diabet.2014.11.004

22. Williams Textbook of Endocrinology — 14th Edition [cited 13.09.2022]. Available from: https://www.elsevier.com/books/williams-textbook-of-endocrinology/melmed/978-0-323-55596-8

23. Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med. 2010;103(4):139-147. doi: https://doi.org/10.1258/jrsm.2010.090254

24. Ahmedani MY, Alvi SFD, Haque MSU, et al. Implementation of Ramadan-specific diabetes management recommendations: a multi-centered prospective study from Pakistan. J Diabetes Metab Disord. 2014;13(1):37. doi: https://doi.org/10.1186/2251-6581-13-37

25. Hassanein M, Afandi B, Yakoob Ahmedani M, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes Res Clin Pract. 2022;185(1):109185. doi: https://doi.org/10.1016/j.diabres.2021.109185

26. Abdelgadir EIE, Hafidh K. Comparison of Incidences, hospital stay and precipitating factors of diabetic ketoacidosis in Ramadan and the following month in three major hospitals in United Arab Emirates. A prospective observational study. J Diabetes Metab. 2016;6(3):109185. doi: https://doi.org/10.4172/2155-6156.1000514

27. Saadatnia M, Zare M, Fatehi F, et al. The effect of fasting on cerebral venous and dural sinus thrombosis. Neurol Res. 2009;31(8):794-798. doi: https://doi.org/10.1179/016164109X12445505689481

28. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet Lond Engl. 1999;354(9188):1435-1439. doi: https://doi.org/10.1016/S0140-6736(99)01376-8

29. Upala S, Sanguankeo A, Congrete S, et al. Sleep duration and insulin resistance in individuals without diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2015;109(3):e11-12. doi: https://doi.org/10.1016/j.diabres.2015.06.003

30. Rao MN, Neylan TC, Grunfeld C, et al. Subchronic sleep restriction causes tissue-specific insulin resistance. J Clin Endocrinol Metab. 2015;100(4):1664-1671. doi: https://doi.org/10.1210/jc.2014-3911

31. Bravis V, Hui E, Salih S, et al. Ramadan Education and Awareness in Diabetes (READ) programme for Muslims with Type 2 diabetes who fast during Ramadan. Diabet Med. 2010;27(3):327-331. doi: https://doi.org/10.1111/j.1464-5491.2010.02948.x

32. Ahmedani MY, Haque MS, Basit A, et al. Ramadan Prospective Diabetes Study: the role of drug dosage and timing alteration, active glucose monitoring and patient education. Diabet Med J Br Diabet Assoc. 2012;29(6):709-715. doi: https://doi.org/10.1111/j.1464-5491.2011.03563.x

33. Olczuk D, Priefer R. A history of continuous glucose monitors (CGMs) in self-monitoring of diabetes mellitus. Diabetes Metab Syndr. 2018;12(2):181-187. doi: https://doi.org/10.1016/j.dsx.2017.09.005

34. Benaji B, Mounib N, Roky R, et al. Diabetes and Ramadan: review of the literature. Diabetes Res Clin Pract. 2006;73(2):117-125. doi: https://doi.org/10.1016/j.diabres.2005.10.028

35. Nutrition issues [Internet]. [cited 15.05.2022]. Available from: http://www.daralliance.org/daralliance/en/dr/nutrition-issues.html

36. Shaltout I, Zakaria A, Abdelwahab AM, et al. Culturally based pre-Ramadan education increased benefits and reduced hazards of Ramadan fasting for type 2 diabetic patients. J Diabetes Metab Disord. 2020;19(1):179-186. doi: https://doi.org/10.1007/s40200-020-00489-1

37. Trabelsi K, Chtourou H. Teaching physical education during Ramadan observance: Practical recommendations. Int J Sport Stud Health. 2019;In Press. doi: https://doi.org/10.5812/intjssh.88013

38. Dedov II, Shestakova MV, Mayorov AYu et al. Standards of specialized diabetes care. Diabetes Mellitus. 2021;24(S1):1-235 (In Russ.). doi: https://doi.org/10.14341/DM12802

39. Papanas N, Katsiki N, Hatzitolios AI, et al. Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2011;12(10):1457-1461. doi: https://doi.org/10.1517/14656566.2011.568477

40. Vasan S, Thomas N, Bharani, et al. A double-blind, randomized, multicenter study evaluating the effects of pioglitazone in fasting Muslim subjects during Ramadan. Int J Diabetes Dev Ctries. 2006;26(2):70. doi: https://doi.org/10.4103/0973-3930.28276

41. Lv W, Wang X, Xu Q, et al. Mechanisms and characteristics of sulfonylureas and glinides. Curr Top Med Chem. 2020;20(1):37-56. doi: https://doi.org/10.2174/1568026620666191224141617

42. Bakiner O, Ertorer ME, Bozkirli E, et al. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetol. 2009;46(1):63-65. doi: https://doi.org/10.1007/s00592-008-0062-7

43. Sari R, Balci MK, Akbas SH, et al. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res. 2004;30(2):169-177. doi: https://doi.org/10.1081/erc-200027375

44. Cesur M, Corapcioglu D, Gursoy A, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract. 2007;75(2):141-147. doi: https://doi.org/10.1016/j.diabres.2006.05.012

45. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206. doi: https://doi.org/10.1001/jama.298.2.194

46. Brady EM, Davies MJ, Gray LJ, et al. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab. 2014;16(6):527-536. doi: https://doi.org/10.1111/dom.12249

47. Azar ST, Echtay A, Wan Bebakar WM, et al. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial. Diabetes Obes Metab. 2016;18(10):1025-1033. doi: https://doi.org/10.1111/dom.12733

48. Hassanein MM, Sahay R, Hafidh K, et al. Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial. Diabetes Res Clin Pract. 2019;150(2):331-341. doi: https://doi.org/10.1016/j.diabres.2019.01.035

49. Lee SWH, Lee JY, Tan CSS, et al. Strategies to make Ramadan fasting safer in type 2 diabetics: A systematic review and network meta-analysis of randomized controlled trials and observational studies. Medicine (Baltimore). 2016;95(2):e2457. doi: https://doi.org/10.1097/MD.0000000000002457

50. Loh HH, Yee A, Loh HS, et al. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis. Prim Care Diabetes. 2016;10(3):210-219. doi: https://doi.org/10.1016/j.pcd.2015.09.001

51. Niswender KD. Basal insulin: physiology, pharmacology, and clinical implications. Postgrad Med. 2011;123(4):17-26. doi: https://doi.org/10.3810/pgm.2011.07.2300

52. Hassanein M, Buyukbese MA, Malek R, et al. Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study. Diabetes Res Clin Pract. 2020;166(2):108189. doi: https://doi.org/10.1016/j.diabres.2020.108189

53. Pathan F, Latif ZA, Sahay RK, et al. Update to South Asian consensus guideline: Use of newer insulins in diabetes during Ramadan Revised Guidelines on the use of insulin in Ramadan. J Pak Med Assoc. 2016;66(6):777-778.

54. Hassanein M, Echtay AS, Malek R, et al. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during . Diabetes Res Clin Pract. 2018;(135):218-226. doi: https://doi.org/10.1016/j.diabres.2017.11.027

55. Filippatos TD, Liontos A, Papakitsou I, et al. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019;131(2):82-88. doi: https://doi.org/10.1080/00325481.2019.1581971

56. Wan Seman WJ, Kori N, Rajoo S, et al. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes Obes Metab. 2016;18(6):628-632. doi: https://doi.org/10.1111/dom.12649ъ